[1]赵菲 刘永铭.抗炎类药物对射血分数保留性心力衰竭患者心外膜脂肪组织的影响[J].心血管病学进展,2022,(1):41-43.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.011]
　ZHAO Fei,LIU Yongming.Effects of Anti-Inflammatory Drugs on Epicardial Adipose Tissue in Patients with Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(1):41-43.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.011]
点击复制

抗炎类药物对射血分数保留性心力衰竭患者心外膜脂肪组织的影响()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年1期
页码:
41-43
栏目:
出版日期:
2022-01-25

文章信息/Info

Title:
Effects of Anti-Inflammatory Drugs on Epicardial Adipose Tissue in Patients with Heart Failure with Preserved Ejection Fraction
作者:
赵菲1 刘永铭 2
(1.兰州大学第一临床医学院,甘肃 兰州　730000;2.兰州大学第一医院老年心血管科/甘肃省老年疾病临床医学研究中心,甘肃 兰州 730000)
Author(s):
ZHAO Fei1;  LIU Yongming2
(1.The First Clinical Medical College of Lanzhou University,Lanzhou 730000,Gansu,China2.Geriatric Cardiovascular Department,The First Hospital of Lanzhou University,Gansu Provincial Clinical Research Center for Geriatric Diseases,Lanzhou 730000,Gansu,China)
关键词:
抗炎药; 心外膜脂肪组织; 射血分数保留性心力衰竭
Keywords:
Anti-inflammatory drugs; Epicardial adipose tissue; Heart failure with preserved ejection fraction
DOI:
10.16806/j.cnki.issn.1004-3934.2022.01.011
摘要:
心外膜脂肪组织在心血管疾病中起着重要作用。近年来研究发现，慢性炎症或代谢紊乱可引起心外膜脂肪组织分泌脂肪因子及游离脂肪酸，进一步导致心功能障碍，最终加快心力衰竭的发展，尤其是射血分数保留性心力衰竭。临床研究证实抗炎类药物（如他汀类药物和抗细胞因子制剂）能降低心外膜脂肪组织厚度，改善炎症状态，有利于降低射血分数保留性心力衰竭患者的死亡风险，现对抗炎类药物对射血分数保留性心力衰竭患者心外膜脂肪组织的影响进行系统综述。
Abstract:
Epicardial adipose tissue(EAT) plays an important role in cardiovascular disease. Recent studies have found that chronic inflammation or metabolic disorder can cause EAT to secrete adipokines and free fatty acids,further lead to cardiac dysfunction,and finally accelerate the development of heart failure,especially heart failure with preserved ejection fraction(HFpEF). Clinical studies have confirmed that anti-inflammatory drugs(statins and anti-cytokine agents) can reduce EAT thickness,improve the state of inflammation,and reduce the risk of death in patients with HFpEF. The effects of anti-inflammatory drugs on EAT in patients with HFpEF are systematically reviewed in this paper.

参考文献/References:

[1] Ponikowski P,Voors AA,Anker SD,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC). Developed with the special contribution of the Heart Failure Association(HFA) of the ESC[J]. Eur J Heart Fail,2016,18(8):891-975.

[2] van Riet EE,Hoes AW,Wagenaar KP,et al. Epidemiology of heart failure:the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review[J]. Eur J Heart Fail,2016,18(3):242-252.

[3] 廖玉华,杨杰孚,张健,等. 舒张性心力衰竭诊断和治疗专家共识[J]. 临床心血管病杂志,2020,36(1):1-10.

[4] Farkhondeh T,Llorens S,Pourbagher-Shahri AM,et al. An overview of the role of adipokines in cardiometabolic diseases[J]. Molecules,2020,25(21):5218.

[5] Villasante Fricke AC,Iacobellis G. Epicardial adipose tissue:clinical biomarker of cardio-metabolic risk[J]. Int J Mol Sci,2019,20(23):5989.

[6] van Woerden G,Gorter TM,Westenbrink BD,et al. Epicardial fat in heart failure patients with mid-range and preserved ejection fraction [J]. Eur J Heart Fail,2018,20(11):1559-1566.

[7] Hunt SC,Davidson LE,Adams TD,et al. Associations of visceral,subcutaneous,epicardial,and liver fat with metabolic disorders up to 14 years after weight loss surgery[J]. Metab Syndr Relat Disord,2021,19(2):83-92.

[8] Matloch Z,Kotulák T,Haluzík M. The role of epicardial adipose tissue in heart disease[J]. Physiol Res,2016,65(1):23-32.

[9] Song Y,Song F,Wu C,et al. The roles of epicardial adipose tissue in heart failure[J]. Heart Fail Rev,2020,Jun 29. DOI:10.1007/s10741-020-09997-x. Epub ahead of print.

[10] Iacobellis G,Barbaro G. The double role of epicardial adipose tissue as pro- and anti-inflammatory organ[J]. Horm Metab Res,2008,40(7):442-445.

[11] Iozzo P. Myocardial,perivascular,and epicardial fat[J]. Diabetes Care,2011,34(suppl 2):S371-S379.

[12] Kitzman DW,Shah SJ. The HFpEF obesity phenotype:the elephant in the room[J]. J Am Coll Cardiol,2016,68(2):200-203.

[13] Packer M. Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium[J]. J Am Coll Cardiol,2018,71(20):2360-2372.

[14] Rayner JJ,Banerjee R,Holloway CJ,et al. The relative contribution of metabolic and structural abnormalities to diastolic dysfunction in obesity[J]. Int J Obes(Lond),2018,42(3):441-447.

[15] Wu CK,Lee JK,Hsu JC,et al. Myocardial adipose deposition and the development of heart failure with preserved ejection fraction[J]. Eur J Heart Fail,2020,22(3):445-454.

[16] Rafeh R,Viveiros A,Oudit GY,et al. Targeting perivascular and epicardial adipose tissue inflammation:therapeutic opportunities for cardiovascular disease[J]. Clin Sci(Lond),2020,134(7):827-851.

[17] Persson CE,Bj?rck L,Lagergren J,et al. Risk of heart failure in obese patients with and without bariatric surgery in Sweden—A registry-based study[J]. J Card Fail,2017,23(7):530-537.

[18] Smail H,Baciu A,Dacher JN,et al. Surgical resection of circumferential epicardial adipose tissue hypertrophy:case report and systematic review of the literature[J]. J Thorac Cardiovasc Surg,2016,151(2):e27-e30.

[19] Kitzman DW,Brubaker P,Morgan T,et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction:a randomized clinical trial[J]. JAMA,2016,315(1):36-46.

[20] Vest AR,Patel P,Schauer PR,et al. Clinical and echocardiographic outcomes after bariatric surgery in obese patients with left ventricular systolic dysfunction[J]. Circ Heart Fail,2016,9(3):e002260.

[21] Patel VB,Shah S,Verma S,et al. Epicardial adipose tissue as a metabolic transducer:role in heart failure and coronary artery disease[J]. Heart Fail Rev,2017,22(6):889-902.

[22] Packer M. Drugs that ameliorate epicardial adipose tissue inflammation may have discordant effects in heart failure with a preserved ejection fraction as compared with a reduced ejection fraction[J]. J Card Fail,2019,25(12):986-1003.

[23] Raggi P,Gadiyaram V,Zhang C,et al. Statins reduce epicardial adipose tissue attenuation independent of lipid lowering:a potential pleiotropic effect[J]. J Am Heart Assoc,2019,8(12):e013104.

[24] Rafeh R,Viveiros A,Oudit GY,et al. Targeting perivascular and epicardial adipose tissue inflammation:therapeutic opportunities for cardiovascular disease[J]. Clin Sci(Lond),2020,134(7):827-851.

[25]Gómez-Garre D,González-Rubio ML,Mu?oz-Pacheco P,et al. Rosuvastatin added to standard heart failure therapy improves cardiac remodelling in heart failure rats with preserved ejection fraction[J]. Eur J Heart Fail,2010,12(9):903-912.

[26] Alexopoulos N,Melek BH,Arepalli CD,et al. Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women:a substudy of the BELLES trial(Beyond Endorsed Lipid Lowering with EBT Scanning)[J]. J Am Coll Cardiol,2013,61(19):1956-1961.

[27] Dirajlal-Fargo S,Kinley B,Jiang Y,et al. Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV:randomized placebo-controlled trial[J]. AIDS,2015,29(3):313-321.

[28] Preiss D,Campbell RT,Murray HM,et al. The effect of statin therapy on heart failure events:a collaborative meta-analysis of unpublished data from major randomized trials[J]. Eur Heart J,2015,36(24):1536-1546.

[29] Tsujimoto T,Kajio H. Favorable effects of statins in the treatment of heart failure with preserved ejection fraction in patients without ischemic heart disease[J]. Int J Cardiol,2018,255:111-117.

[30] Marume K,Takashio S,Nagai T,et al. Effect of statins on mortality in heart failure with preserved ejection fraction without coronary artery disease—Report from the JASPER study[J]. Circ J,2019,83(2):357-367.

[31] Ashton E,Windebank E,Skiba M,et al. Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study[J]. Int J Cardiol,2011,146(3):404-407.

[32] Mazurek T,Zhang L,Zalewski A,et al. Human epicardial adipose tissue is a source of inflammatory mediators[J]. Circulation,2003,108(20):2460-2466.

[33] van Tassell BW,Arena R,Biondi-Zoccai G,et al. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction(from the D-HART pilot study)[J]. Am J Cardiol,2014,113(2):321-327.

[34] Everett BM,Cornel JH,Lainscak M,et al. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure[J]. Circulation,2019,139(10):1289-1299.

[35] Wolfe F,Michaud K. Heart failure in rheumatoid arthritis:rates,predictors,and the effect of anti-tumor necrosis factor therapy[J]. Am J Med,2004,116(5):305-311.

相似文献/References:

[1]郑涛,综述,凌智瑜,等.心外膜脂肪组织与心房颤动[J].心血管病学进展,2016,(4):372.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.012]
　ZHENG Tao,LING Zhiyu.Epicardial Adipose Tissue and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):372.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.012]
[2]刘静 彭礼清.心外膜脂肪组织定量评价的影像学进展[J].心血管病学进展,2020,(9):922.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.009]
　LIU Jing,PENG Liqing.Quantitative Evaluation of Epicardial Adipose Tissue Measured by Different Imaging Methods[J].Advances in Cardiovascular Diseases,2020,(1):922.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.009]
[3]周振 江洪.脂肪组织在心房颤动中的研究进展[J].心血管病学进展,2023,(3):224.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.008]
　ZHOU Zhen,JIANG Hong.Role of Adipose Tissue in Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2023,(1):224.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.008]
[4]张瑶 王鑫 王鹏 李瑾.心外膜脂肪组织在心力衰竭中的研究进展[J].心血管病学进展,2023,(11):1010.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.012]
　ZHANG YaoWANG XinWANG PengLI Jin.Epicardial Adipose Tissue in Heart Failure[J].Advances in Cardiovascular Diseases,2023,(1):1010.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.012]

更新日期/Last Update: 2022-02-17